Brief: Phase Iii Clinical Study Ind Accepted In China For Alimera’S Fluocinolone Acetonide Intravitreal Implant
08/06/2022 13:26
June 8 (Reuters) - Alimera Sciences Inc ALIM.O :
* PHASE III CLINICAL STUDY IND ACCEPTED IN CHINA FOR
ALIMERA’S
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT
Source text for Eikon: ID:nGNXDsKGb
Further company coverage: ALIM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger